Inflammation, glucose metabolism, and nutritional markers in relation to all-cause and cardiac mortality among initial hemodialysis patients: a multicenter cohort study

炎症、葡萄糖代谢和营养指标与初次血液透析患者全因死亡率和心脏死亡率的关系:一项多中心队列研究

阅读:2

Abstract

OBJECTIVE: To investigate the prognostic value of inflammatory biomarkers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR), glucose metabolism (glucose-to-lymphocyte ratio, GLR), and nutritional (albumin, ALB) biomarkers for predicting all-cause and cardiac mortality in patients initiating hemodialysis (HD), and evaluates their incremental value when integrated into traditional risk models. METHODS: A retrospective cohort of 795 initial HD patients (2014-2020) was analyzed, with follow-up through 2022. Cox proportional hazards models were used to assess associations between biomarkers and mortality. Predictive performance was evaluated using time-dependent ROC curves, C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Patients were randomly assigned to training (n = 557) and validation (n = 238) sets, and a survival nomogram was developed based on a full-risk model incorporating both traditional and biomarker variables. RESULTS: Elevated NLR, PLR, and GLR were independently associated with increased all-cause and cardiac mortality, whereas lower LMR and ALB were protective (all p < 0.05). NLR exhibited the highest predictive accuracy across 1-, 3-, and 5-year intervals, followed by GLR and PLR. The full-risk model significantly outperformed the baseline model, with AUCs up to 0.980 and 0.966 for all-cause mortality and 0.947 and 0.978 for cardiac mortality in training and validation sets, respectively (all p < 0.001). Improvements in C-index, NRI, and IDI supported its enhanced predictive utility. CONCLUSION: Incorporating inflammatory, glucose metabolism and nutritional biomarkers into traditional risk models substantially improves long-term mortality risk stratification in initial HD patients, offering a robust, clinically applicable tool to support individualized prognostic assessment and intervention planning.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。